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Background: Delivery of SBRT to central thoracic tumours within 2 cm of the proximal bronchial tree
(PBT), and especially ultra-central tumours which directly abut the PBT, has been controversial due to
concerns about high risk of toxicity and treatment-related death when delivering high doses close to crit-
ical mediastinal structures. We present dosimetric and clinical outcomes from a group of oligometastatic
patients treated with a risk-adapted SBRT approach.
Methods: Between September 2015 and October 2018, 27 patients with 28 central thoracic oligometas-
tases (6 moderately central, 22 ultra-central) were treated with 60 Gy in 8 fractions under online CBCT
guidance. PTV dose was compromised where necessary to meet mandatory OAR constraints. Patients
were followed up for toxicity and disease status.
Results: Mandatory OAR constraints were met in all cases; this required PTV coverage compromise in 23
cases, with V100% reduced to <70% in 11 cases. No acute or late toxicities of Grade  3 were reported. One
and 2 year in-field control rates were 95.2% and 85.7% respectively, progression-free survival rates were
42.8% and 23.4% respectively, and overall survival rates were 82.7% and 69.5% respectively. No significant
differences were seen in control or survival rates by extent of PTV underdosage or between moderately
and ultra-central cases.
Conclusion: It appears that compromising PTV coverage to meet OAR constraints allows safe and effective
delivery of SBRT to moderately and ultra-central tumours, with low toxicity rates and high in-field con-
trol rates. This treatment can be delivered on standard linear accelerators with widely available imaging
technology.
 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy &
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Stereotactic body radiotherapy (SBRT) is an established treat-
ment modality for peripheral early stage non-small cell lung can-
cers (NSCLC) in patients who are unsuitable for surgery,
achieving excellent local control rates and low toxicity [1]. More
recently SBRT has emerged as an important treatment modality
in the management of oligometastases, with promising outcomes
following SBRT to pulmonary metastases [2]. In particular, the
recent SABR-COMET trial reported an increase in median survival
of 13 months associated with SBRT to oligometastatic disease [3].The use of SBRT in treating central thoracic tumours, both pri-
mary and metastatic, has been controversial, following Timmer-
man et al.’s [4] phase II study showing severe toxicity and
treatment-related death when treating central early stage NSCLC
with 60–66 Gy in 3 fractions. This led to the definition of the ‘‘no
fly zone” (NFZ): the area within 2 cm of the proximal bronchial tree
(PBT) within which SBRT was not recommended. Several single-
centre studies have now demonstrated that acceptable toxicity
rates can be achieved when treating central tumours with lower
doses per fraction [5–11].
More recently a subgroup of tumours within the central chest
has been recognised as potentially being at higher risk of
treatment-related toxicity, termed ‘‘ultra-central” [12], and gener-
ally defined as those tumours directly abutting the PBT. Published
data on the safety of treating ultra-central tumours with SBRT is
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patients treated for central or peripheral tumours [12–14], others
report high toxicity rates [15–17].
When treating tumours within the NFZ there is a trade-off
between delivering an ablative dose to the tumour and avoiding
causing excessive toxicity by overdosing OARs. There is currently
no consensus regarding the best approach, with a variety of dose
fractionations and OAR constraints being used, and some groups
prioritising PTV dose coverage while others prioritise OAR sparing.
It is therefore difficult to draw conclusions on the safety and effi-
cacy of SBRT to central tumours.
At our centre, central pulmonary or nodal oligometastases are
treated with SBRT using a risk-adapted approach: a dose fraction-
ation of 60 Gy in 8 fractions is prescribed, and dose coverage of up
to 30% of the PTV is compromised where necessary to meet
mandatory OAR constraints. This study examines our approach to
planning, verification and delivery of SBRT to pulmonary or nodal
oligometastases within the NFZ. Specifically, we aim to investigate
whether PTV coverage compromises have a significant effect on
control rates or possible implications relating to survival, and
whether low acute and late toxicity rates are achieved.Materials and methods
Patients
All patients who received SBRT at our centre for oligometas-
tases within the NFZ between September 2015 and October 2018
were included in analyses. All patients gave written informed con-
sent for use of their information for research purposes, data was
collected retrospectively and was anonymised prior to analysis.
Work was carried out in accordance with the Declaration of
Helsinki.
Metastases were described as ultra-central if the GTV directly
abutted the PBT, or moderately central otherwise.Treatment planning
Patients were positioned for treatment supine with arms above
the head supported by a vacuum bag. A 2.5 mm slice planning scan
consisting of a contrast-enhanced 3DCT and non-enhanced 4DCT
was acquired using a GE Optima CT580 CT scanner and the Varian
Real-Time Position Management System (Varian Medical Systems,
Palo Alto, CA).
The GTV and OARs – PBT, oesophagus, heart (including pericar-
dial sac), lungs and spinal canal – were outlined on 3DCT. An ITV
was outlined using the maximum inhale and exhale phases of
the 4DCT, and all other respiratory phases were reviewed to ensure
the full range of tumour motion was encompassed. A 3–5 mmmar-
gin was added to the ITV to generate the PTV; choice of margin in
each case was individualised by the SBRT MDT following qualita-
tive assessment of the challenges of image matching in each indi-
vidual case.
All patients received a prescribed dose of 60 Gy in 8 fractions,
delivered on alternate week days. Prescription dose was not pre-
scribed to a specific isodose line but rather by direct optimisation
within the treatment planning software for prescription dose to
cover 95% of PTV with compromise to meet mandatory OAR con-
straints as necessary. Maximum dose within PTV was constrained
to greater than 120% and less than 130% of prescription to allow for
suitable dose fall off associated with a SBRT treatment. Coverage
criterion of 95% of PTV receiving prescription dose was relaxed to
a minimum of 70% of PTV receiving prescription dose to allow
for OAR constraints being respected. Mandatory dose constraints
are shown in Table 3. Where the PTV overlapped with mediastinalstructures, dose to the overlap portion was maintained to the high-
est level achievable while respecting the relevant mandatory OAR
constraints, as shown in Fig. 1. Treatments were planned in Varian
Eclipse v13 (Varian Medical Systems, Palo Alto, CA) using the AAA
dose calculation algorithm and a 0.15 cm dose calculation grid size.
Treatment was delivered on Varian Clinac iX linear accelerators
using IMRT or VMAT.
Treatment verification
Before each fraction a kV cone beam CT (CBCT) was acquired
and reviewed, and a couch correction performed for any displace-
ment of >1 mm on the right-left (RL), superior-inferior (SI) or
anterior-posterior (AP) axes. The PBT position was prioritised in
the online match to ensure planned doses to this structure were
not exceeded, while also ensuring the lesion was well covered by
the PTV. Treatment verification was performed by a team of radia-
tion therapists (RTTs) who are experienced in reviewing CBCTs.
Treatment accuracy was assessed by analysing data on initial
set-up errors (discrepancy between the initial couch position and
online CBCT match) for all fractions, and residual set-up errors
(displacement between the online match and an offline re-
match) for fractions 1–5 for the first 10 patients in the cohort.
Follow-up
Patients were assessed for toxicity and disease status at 3, 6, 12,
18 and 24 months post-treatment, with an additional follow-up
1 month post-treatment to assess toxicity only. Toxicity was cate-
gorised according to CTCAE version 4.0, and defined as acute if
occurring within 3 months of treatment, or late. Disease status
was assessed using the most appropriate imaging and/or biochem-
ical investigation according to disease histology. Progression was
defined as in-field if occurring within the treated volume, locore-
gional if outside the treated volume but in adjacent nodal regions,
or distant otherwise. Patients were followed up either at our centre
or locally if referred from elsewhere.
Statistical analysis
Differences in dose metrics were assessed for significance using
the Mann-Whitney U test. In-field control (IFC), progression-free
survival (PFS), and overall survival (OS) were calculated using
Kaplan-Meier methods, with comparisons between groups per-
formed using the log-rank test. Patients were censored at date of
last disease assessment for IFC and PFS analyses, and at date of last
contact in analyses of OS. Statistical analyses were performed
using R (R Foundation for Statistical Computing, Vienna, Austria).
A p-value of < 0.05 was considered to represent statistical
significance.Results
Patient and tumour characteristics
Twenty-seven patients were included in analyses. Median age
was 71 years (range 38–89 years), 11 were female and 16 male.
Most frequent primary sites were colorectal (16, 59.3%) and renal
(5, 18.5%). Patient details are shown in Table 1.
Tumour characteristics are summarised in Table 2. One patient
had 2 central tumours treated concurrently. Twenty-two (78.6%)
ultra-central and 6 (21.4%) moderately central tumours were trea-
ted, 10 (35.7%) were pulmonary metastases and 18 (64.3%) were
nodal: 8 (29.6%) mediastinal and 10 (35.7%) hilar. Tumour loca-
tions in relation to the PBT are illustrated in Fig. 2.
Fig. 1. Axial image from planning CT for a case where PTV overlapped with proximal bronchial tree and oesophagus, requiring compromise to PTV dose coverage. Isodose
lines represent absolute dose in Gray.
Table 1
Characteristics of cohort.
n % Median Range
Primary site
Colorectal 16 59.3
Renal 5 18.5
Lung 2 7.4
Melanoma 1 3.7
Pancreas 1 3.7
Prostate 1 3.7
Thyroid 1 3.7
Performance status
0 13 48.1
1 14 51.9
Lung function
FEV1 % 93.2 59.1–127.0
FVC % 98.3 74.9–148.0
Previous lung treatment
None 10 37.0
Surgery 13 48.1
Radiofrequency ablation (RFA) 2 7.4
Surgery & RFA 2 7.4
Previous chemotherapy
Yes 16 59.3
No 11 40.7
Total 27
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6.6 cm3). GTV motion on 4DCT ranged between 0 and 14 mm lon-
gitudinally (median 6 mm), 0 and 11 mm laterally (median 3 mm),
and 0 and 16 mm anteroposteriorly (median 3 mm). An ITV to PTV
margin of 3 mm was used in 10 cases, and 5 mm was used in 18
cases. PTV volumes ranged from 8.3 cm3 to 106.4 cm3 (median
32.8 cm3), and 26 (92.9%) PTVs overlapped with mediastinal struc-
tures: 25 (89.3%) with the PBT, 13 (46.4%) with the heart, and 3
(10.7%) with the oesophagus. The volume of PTV-OAR overlap ran-
ged from 0.0 cm3 to 25.1 cm3 (median 2.1 cm3), which was
between 0.0% and 48.6% of the total PTV volume (median 6.3%).Dosimetry
A PTV D95% 100% of prescribed dose was achieved in only 4
(14.3%) cases (3 moderately central, 1 ultra-central); for theremaining 24 (85.7%) cases it was necessary to underdose the
PTV to meet mandatory OAR constraints. A significantly higher
PTV D95% was achieved for moderately than ultra-central cases,
and similarly for GTV and ITV D95%, as shown in Table 3. The vol-
ume of PTV receiving 100% of prescription dose ranged from 35.5%
to 99.5%, was significantly higher for moderately than ultra-central
cases, and was <70% in 11 cases, all ultra-central. Minimum dose
delivered to 0.1 cm3 of the PTV ranged from 32.1 Gy to 60.5 Gy,
with significantly higher minimum doses delivered to moderately
than ultra-central cases, see Table 3. Median PTV dose was
>60 Gy for all moderately central cases, and all but 3 ultra-
central cases.
For the non-overlap portion of the PTV, minimum dose to
0.1 cm3 was again significantly higher in moderately central than
ultra-central cases. The volume of non-overlap PTV receiving
100% prescription dose was significantly lower for ultra-central
cases and <70% in 6 cases.
Median D95% to GTV was 88.3% for cases treated with a 3 mm
PTVmargin (range 74.1–109.1%) and for those with a 5 mmmargin
median D95% was 89.7% (range 70.7–117.9%). For ITV, median
D95% was 73.2% (range 80.9–107.6%) for 3 mm margin and 76.1%
(range 68.0–118.3%) for 5 mm margin. Differences in D95% for
cases treated with 3 mm and 5 mm margins were non-significant
(p = 0.90 and p = 0.13 for GTV and ITV respectively).
OAR doses were kept below mandatory constraints in all cases.
All OAR dose metrics, with the exception of lung V20Gy, were
higher for ultra-central than moderately central cases, as shown
in Table 3. Differences were significant for PBT and spinal canal.
Two patients received concurrent SBRT to an ipsilateral periph-
eral pulmonary metastasis. In one case the peripheral GTV abutted
the central GTV and both were encompassed in a single PTV. In the
other case separate plans were delivered, with the peripheral
tumour receiving 60 Gy in 5 fractions. Cumulative doses from the
two plans were used in analyses.Set-up error
The mean (range) absolute initial set-up error was 2.0 mm (0–
12 mm) on the RL axis, 4.0 mm (0–17 mm) on the SI axis, and
Table 2
Characteristics of tumours treated in the cohort.
n % Median Range
Tumour location
Moderately central 6 21.4
Ultra-central 22 78.6
Metastasis type
Lung 10 35.7
Mediastinal node 8 28.6
Hilar node 10 35.7
OARs overlapped by PTV
None 2 7.1
PBT 13 46.4
Oesophagus 0 0.0
Heart 1 3.6
PBT & oesophagus 0 0.0
PBT & heart 9 32.1
Oesophagus & heart 0 0.0
PBT, oesophagus & heart 3 10.7
GTV volume (cm3) 6.6 0.5–48.3
PTV volume (cm3) 32.8 8.3–106.4
Overlapping PTV volume
cm3 2.1 0.0–25.1
% of PTV 6.3 0.0–48.6
Non-overlapping PTV volume (cm3) 28.9 6.0–94.3
Total 28
Fig. 2. Illustration of approximate location and size of GTVs (red, solid outline) with
respect to the proximal bronchial tree (orange, dashed outline). (For interpretation
of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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required at 15 (6.9%) fractions: in 13 cases this was following cor-
rection of a large displacement, in 1 case following repositioning of
the patient due to excessive rotation, and in 1 case following an
equipment fault. Mean (range) absolute residual set-up error was
0.4 mm (0–2 mm) RL, 0.8 mm (0–3 mm) SI, and 0.5 mm (0–
2 mm) AP.
Follow-up
Median follow-up for disease status was 11.6 months (in-
terquartile range 6.5–19.4 months). Two patients (7.4%) experi-
enced in-field progression, both of whom had ultra-central hilar
nodal metastases treated. The volume of PTV receiving prescription
dose in these two patients was 65.5% and 62.2%. In one patient this
was the first and only progression event, occurring at 14.3 months
following SBRT. The other patient had distant progression first at
2.6 months, with in-field progression occurring 5.1 months follow-
ing SBRT. Locoregional progression occurred in 6 patients (22.2%).
Distant progression occurred in 13 patients (48.1%). Four patients
(14.8%) have received systemic therapy following progression.One and 2 year IFC rates were 95.2% (95% confidence interval
[CI] 86.6–100.0%) and 85.7% (95% CI 68.3–100.0%) respectively.
One and 2 year PFS rates were 42.8% (95% CI 26.1–70.1%) and
23.4% (95% CI 9.8–55.9%) respectively. There were no significant
differences in IFC or PFS by tumour location, metastasis type, pri-
mary site, GTV volume or PTV coverage (see Table 4). Kaplan-
Meier plots for IFC and PFS are shown in Fig. 3.
Median follow-up for vital status was 14.3 months (interquar-
tile range 9.4–24.6 months). Six patients (22.2%) died during
follow-up; disease progression had occurred in 5 of these cases.
One and 2 year OS rates were 82.7% (95% CI 68.6–99.7%) and
69.5% (95% CI 51.0–94.7%) respectively; Fig. 3 shows the Kaplan-
Meier plot for OS. Patients whose primary disease was colorectal
or renal had significantly higher 1 year OS rates than those with
other primary diagnoses, as shown in Table 4. No other significant
differences in OS were seen with varying tumour characteristics or
dose coverage.
Treatment was tolerated well, with no Grade  3 toxicities
observed. Three (11.1%) cases of Grade 2 acute toxicity were seen,
all in patients treated for ultra-central tumours: 1 Grade 2 dyspha-
gia which was seen at 1 month following SBRT and had resolved by
the 3 month follow-up, and 2 cases of Grade 2 radiation pneumoni-
tis which resolved with steroid treatment. One (3.7%) Grade 2 late
toxicity has been reported; this was fatigue, which was reported at
6 months and had resolved by the subsequent follow-up.Discussion
Oligometastasis is increasingly being recognised as a state dur-
ing which radical local therapy can lead to long-term control and
delay the need for systemic therapy with its associated toxicities,
maximising quality of life. Surgical resection of metastases in the
central chest is a major undertaking with high risk of complica-
tions [18], and will be unsuitable in many cases due to co-
morbidities. Data on treating central thoracic metastases with
SBRT is limited, as the delivery of SBRT within the NFZ has been
controversial since an early study in NSCLC demonstrated severe
toxicity and high rates of treatment-related death [4]. Although
several retrospective studies have now demonstrated that moder-
ately central primary and metastatic tumours can be treated safely
Table 3
Dosimetry achieved in moderately and ultra-central cases, compared using the Mann-Whitney U test.
Mandatory dose constraint Moderately central Ultra-central All
Median Range Median Range p value Median Range
PTV
D95% (%) 100.4 96.1–103.2 73.6 64.3–100.0 <0.001 75.9 64.3–103.2
V100% (%) 91.9 81.7–99.5 70.3 35.5–95.0 0.001 77.4 35.5–99.5
Minimum dose (Gy) 54.2 44.3–60.5 41.2 32.1–46.9 <0.001 42.0 32.1–60.5
Maximum dose (Gy) 74.2 71.9–77.1 77.0 67.5–83.5 0.10 76.2 67.5–83.5
Median dose (Gy) 66.7 63.5–68.2 64.4 56.7–68.8 0.13 64.5 56.7–68.8
Non-overlapping portion of PTV
V100% (%) 96.3 83.7–99.5 78.3 42.1–95.4 0.001 82.6 42.1–99.5
Minimum dose (Gy) 57.3 46.3–60.5 42.9 32.1–49.5 <0.001 44.2 32.1–60.5
Maximum dose (Gy) 74.2 71.9–77.1 76.7 65.9–81.5 0.19 76.2 65.9–81.5
Median dose (Gy) 66.7 64.3–68.2 65.1 58.1–69.1 0.19 65.2 58.1–69.1
GTV D95% (%) 112.8 99.9–117.9 86.3 70.7–114.4 0.003 89.1 70.7–117.9
ITV D95% (%) 112.3 99.2–118.3 83.1 68.0–109.7 0.003 86.8 68.0–118.3
Organs at risk
PBT Dmax 0.5 cm3 (Gy) 44 Gy 27.4 13.7–43.9 43.3 34.4–44.0 0.045 42.9 13.7–44.0
Oesophagus Dmax 0.5 cm3 (Gy) 40 Gy 17.8 10.7–24.9 22.3 14.1–39.9 0.10 19.6 10.7–39.9
Heart Dmax 0.5 cm3 (Gy) 60 Gy 26.4 4.6–60.0 37.9 1.1–60.0 1.00 34.5 1.1–60.0
Spinal canal 0.1 cm3 (Gy) 32 Gy 10.1 5.5–16.6 20.5 10.9–30.5 0.001 19.0 5.5–30.5
Lungs excluding GTV V20Gy (%) 10% 4.7 4.1–8.0 4.0 1.2–9.6 0.55 4.1 1.2–9.6
Lungs excluding GTV V12.5 Gy (%) 15% 8.3 6.9–13.3 9.2 3.2–15.0 0.80 9.0 3.2–15.0
Table 4
Kaplan-Meier estimates of in-field control, progression-free survival and overall survival rates, compared using the log-rank test.
1 year IFC 95% CI 1 year PFS 95% CI 1 year OS 95% CI
Tumour location
Moderately central 100.0 37.5 8.4–100.0 75.0 42.6–100.0
Ultra-central 94.1 83.6–100.0 42.4 24.7–72.7 84.4 69.7–100.0
p value 0.49 0.59 0.22
Metastasis type
Lung 100.0 77.8 54.9–100.0 87.5 67.3–100.0
Mediastinal node 100.0 16.7 2.8–99.7 68.6 40.3–100.0
Hilar node 88.9 70.6–100.0 36.0 15.0–86.5 88.9 70.6–100.0
p value 0.31 0.27 0.09
Primary site
Colorectal 92.3 78.9–100.0 47.7 28.1–81.0 85.7 69.2–100.0
Renal 100.0 0.0 100.0
Other 100.0 40.0 9.4–100.0 50.0 18.8–100.0
p value 0.53 0.79 0.02
GTV volume
<7.5 cm3 90.9 75.4–100.0 45.6 23.3–89.2 90.0 73.2–100.0
7.5 cm3 100.0 38.1 17.9–81.1 75.0 54.1–100.0
p value 0.79 0.10 0.49
Minimum PTV dose
<42 Gy 100.0 43.5 22.8–83.0 82.5 63.1–100.0
42 Gy 88.9 70.6–100.0 43.7 20.9–91.8 83.3 64.7–100.0
p value 0.81 0.89 0.99
PTV coverage
V100% <70% 88.9 70.6–100.0 50.5 27.3–93.3 80.8 60.0–100.0
V100% >70% 100.0 35.6 15.8–80.5 84.6 67.1–100.0
p value 0.13 0.95 0.78
Overall 95.2 86.6–100.0 42.8 26.1–70.1 82.7 68.6–99.7
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report high toxicity rates [19,20].
The evidence for ultra-central tumours is more equivocal. Three
studies have reported no significant difference in toxicity following
SBRT to moderately central and ultra-central (and in one case
peripheral) lesions [12–14]. However others have reported
increased rates of toxicity and treatment-related death compared
with moderately central tumours [15–17]. Chaudhuri et al. [21]
suggest that these high toxicity rates may be due to increased risk
of haemorrhage caused by use of anti-angiogenic, anti-coagulant or
anti-platelet medications, tumour invasion of proximal bronchi or
pulmonary vasculature, or high doses to these structures. The vari-
ation in reported toxicity rates may also be partly due to the lack of
consensus on the most appropriate dose fractionation schedule,
OAR constraints and method of managing the trade-off betweenPTV coverage and OAR sparing. The use of the terms ‘‘central”
and ‘‘ultra-central” within the literature, as summarised by Ade-
bahr et al. [22] and Rim et al. [23] respectively, is also inconsistent
which may result in comparisons between patient groups that are
not directly comparable.
By prioritising mandatory OAR constraints, we have demon-
strated an apparent initial low toxicity rate for patients who
received SBRT to moderately and ultra-central tumours, as per
our definition. The compromise to PTV coverage required to meet
these constraints exceeded our criterion of 70% PTV receiving
100% prescribed dose in several cases. Although PTV coverage
was <70% in both cases of in-field failure, no significant difference
in in-field control was found based on whether or not this criterion
was met. In-field control rates in this cohort are comparable to
those seen in another series of patients receiving 60 Gy in 8 frac-
Fig. 3. Kaplan Meier plots of in-field control, progression-free survival and overall survival for the whole cohort, with 95% confidence interval.
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range of more intensive dose fractionations [7,9–12,15,16,24]. Sim-
ilar in-field control rates were also seen in patients treated with
57.5–60 Gy in 5 fractions in the RTOG0813 trial [25]. OS rates in
this cohort are comparable with rates from other metastasis-only
series [8,26]. We saw no significant difference in in-field control
or survival between moderately and ultra-central cases. Other
groups comparing these groups have found no significant differ-
ence in control or survival [12–14,16]; Chaudhuri et al. [12] also
found no significant differences in comparisons with peripheral
cases. The only statistically significant difference in control or sur-
vival identified in our cohort was a higher OS rate in patients with
colorectal or renal diagnoses compared with other primary diag-
noses. No difference was seen between control rates in these
groups, and due to the variety of diagnoses in the ‘‘other”
category it is difficult to draw any meaningful conclusion from this
result.
Due to dose being sculpted around OAR-PTV overlap and OAR
doses often being near constraints, treatment delivery must be
highly accurate, to ensure that delivered dose distributions are as
close as possible to those planned. The small residual set-up errors
demonstrate that restricting SBRT image matching to an experi-
enced team of RTTs can ensure consistent and accurate delivery
of central thoracic SBRT. Treatments in this study were delivered
under 3DCBCT image guidance with no respiratory motion man-
agement, however, and increased precision could be achieved with
more specialised image guidance such as 4DCBCT or real-time fidu-
cial tracking, or motion management techniques such as active
breathing control or deep inspiration breath-hold [27]. A recent
study [28] demonstrates the potential of stereotactic MR-guided
adaptive radiotherapy to improve PTV coverage and OAR sparing
when treating ultra-central tumours. However, it is unclear the
degree to which motion management and/or specialist image guid-
ance may improve outcomes through increased precision or simply
through reduction in PTV volume leading to reduced need for dose
compromise in the first instance. Future research in this area
would be prudent.
A limitation of this work is that a variable 3/5mm PTV margin
has been used and this is a potential confounding factor when link-
ing degree of PTV compromise with outcomes. However, GTV/ITV
compromise was comparable when looking at patients treated
with a 3 or 5 mm PTV margin, with no significant difference in
D95% for either volume, and therefore delivered dose to tumour
was similarly compromised irrespective of PTV margin used.
Our study is limited by a small number of patients and short
follow-up times in some cases, which could result in being under-powered to detect significant differences between groups. It is also
possible that toxicity rates may have been underestimated due to
difficulties in obtaining complete follow-up information for some
patients being followed up at their referring hospital. However,
the use of SBRT in this patient population is not widespread and
a cohort of this size adds to the current body of work supporting
delivery of SBRT.
SBRT appears to be a promising local treatment option for cen-
tral chest oligometastases, but the range of approaches taken, dis-
crepancies in terminology, and heterogeneity of patient
populations within the published literature make it difficult to
reach firm conclusions on the safety of SBRT in this scenario. It is
important that consensus is reached to harmonise SBRT delivery
in this clinical context in order to provide patients with the best
chance of long-term control and low risks of toxicity. Where possi-
ble clinical trials such as LungTech [22] and SUNSET [29] should be
supported to help achieve this aim.
Our results from a strictly defined patient group in whom SBRT
was planned and delivered consistently provide important addi-
tional evidence for the efficacy and safety of SBRT within the
NFZ. Furthermore, we present novel data on dosimetry achieved
when compromising PTV coverage to meet OAR constraints, details
on an effective treatment verification approach which ensures
these doses are delivered accurately, and reassuring outcomes
demonstrating that this approach resulted in a low toxicity rate
and did not appear to significantly affect control or survival. While
specialised equipment and novel technological developments have
the potential to improve treatment precision which may lead to
improvements in control and decreased toxicity, this study demon-
strates that SBRT can be safely and effectively delivered to central
thoracic tumours on a conventional linear accelerator, with no res-
piratory management, and with widely available imaging
technology.
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